Green Alpha Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Green Alpha Advisors, LLC

$135 Million
Q1 2024

A detailed history of Green Alpha Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 1,005 shares of VRTX stock, worth $471,063. This represents 0.31% of its overall portfolio holdings.

Number of Shares

1,005

Previous 1,013 0.79%

Holding current value

$471,063

Previous $412,000 1.94%

% of portfolio

0.31%

Previous 0.3%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	SELL	$407.69 - $446.08 $3,261 - $3,568	-8 Reduced 0.79%	1,005 $420,000
Q4 2023 Jan 04, 2024	SELL	$343.0 - $410.68 $61,397 - $73,511	-179 Reduced 15.02%	1,013 $412,000
Q3 2023 Oct 10, 2023	SELL	$338.18 - $362.46 $220,155 - $235,961	-651 Reduced 35.32%	1,192 $414,000
Q2 2023 Jul 06, 2023	BUY	$314.42 - $351.91 $79,233 - $88,681	252 Added 15.84%	1,843 $648,000
Q1 2023 Apr 06, 2023	SELL	$283.23 - $323.1 $12,745 - $14,539	-45 Reduced 2.75%	1,591 $501,000

Q4 2022 Jan 12, 2023	SELL	$285.76 - $321.48 $4,572 - $5,143	-16 Reduced 0.97%	1,636 $0
Q3 2022 Oct 14, 2022	BUY	$273.83 - $305.53 $1,642 - $1,833	6 Added 0.36%	1,652 $478,000
Q2 2022 Jul 08, 2022	SELL	$234.96 - $292.55 $279,367 - $347,841	-1,189 Reduced 41.94%	1,646 $464,000
Q1 2022 Apr 19, 2022	BUY	$221.42 - $260.97 $24,134 - $28,445	109 Added 4.0%	2,835 $740,000
Q4 2021 Jan 12, 2022	BUY	$177.01 - $223.45 $11,151 - $14,077	63 Added 2.37%	2,726 $599,000
Q3 2021 Oct 12, 2021	BUY	$181.39 - $202.99 $48,068 - $53,792	265 Added 11.05%	2,663 $483,000
Q2 2021 Jul 22, 2021	BUY	$187.49 - $221.1 $89,807 - $105,906	479 Added 24.96%	2,398 $484,000
Q1 2021 Jul 22, 2021	BUY	$207.02 - $241.31 $397,271 - $463,073	1,919 New	1,919 $412,000

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.

Account

Green Alpha Advisors, LLC Vertex Pharmaceuticals Inc Transaction History